Interim report
Page 1
Interim report July-September 2026 INTERIM REPORT July-September 2026 Leading the Way in Pancreatic Cancer Diagnostics Immunovia’s mission is to save lives through early detection of pancreatic cancer Q3
Page 2
Interim report July-September 2026 Important events 2 ”Immunovia delivered its best commercial results ever as uptake of the PancreaSure test accelerated in Q3. We added more high-risk surveillance centers than ever before, and test adoption significantly increased. ” Jeff Borcherding, CEO and President, Immunovia AB” Highlights July-September 2026 ● Net sales and operating results for Q3 2026 in line with expectations: Net sales for the period amounted to 843 KSEK (101), comprising revenue from PancreaSure test sales and royalty income. Operating loss was 17.7 MSEK, compared to 25.1 MSEK in the third quarter of 2025. Earnings per share before and after dilution were -0.03 SEK (-0.10). ● Lower operating cash burn: Cash flow from operating activities was -14.9 MSEK, decreased from -16.1 MSEK in Q3 2025. Savings resulted from lower spending on clinical studies. Cash and cash equivalents at the end of the period equaled 19.6 MSEK (26.6). ● Survey shows strong support for blood-based pancreatic cancer screening: Immunovia announced results from the ADHERE survey of 392 high-risk individuals, showing that 91% were comfortable using blood-based testing and 96% would consider it alongside existing imaging methods, supporting PancreaSure’s potential role as a complement to imaging-based surveillance. ● Medicare coverage request for PancreaSure: On September 28, 2026, Immunovia submitted a formal request for Medicare coverage of the PancreaSure test. A positive decision could expand patient access and create a significant future revenue opportunity. ● Rights Issue of approximately SEK 63 million was announced: The Board of Directors resolved on a Rights Issue of approximately SEK 63 million, subject to EGM approval on 29 October 2026. The Rights Issue is approximately 80% secured through subscription undertakings and a guarantee commitment. Proceeds will primarily fund US commercialization of PancreaSure, clinical studies and working capital. Significant events after the period ● PancreaSure demonstrates performance in hereditary and familial high-risk individuals: A peer-reviewed analysis published in the Journal of Clinical Medicine evaluated PancreaSure in individuals at increased risk of pancreatic cancer due to genetic mutations or family history. The test detected 77.5% of early-stage pancreatic cancer cases and demonstrated specificity of 93.6% in this high-risk group. Sensitivity for Stage I cancer was 80.0%. These results will support commercial adoption and Immunovia's reimbursement efforts. Key indicators SEK thousand unless otherwise stated 2026 Jul-Sep 2025 Jul-Sep 2026 Jan-Sep 2025 Jan-Sep 2025 Full year Net sales 843 101 1,598 330 685 Operating earnings/loss -17,680 −25,051 -58,993 -64,009 -80,385 Earnings before tax -17,606 -29,744 -58,870 -128,587 -145,915 Earnings/loss for the period -17,606 -29,744 -58,870 -128,587 -145,915 Earnings per share before dilution (SEK) -0.03 -0.10 -0.09 -0.48 -0.42 Earnings per share after dilution (SEK) -0.03 -0.10 -0.09 -0.48 -0.41 Equity ratio (%) 21% -22% 21% -22% 72% Number of shares at the end of the period 672,666,892 306,083,080 672,666,892 306,083,080 672,666,892 This section highlights material events during and after the reporting period. Previously communicated events during the current financial year are available in Immunovia’s interim reports and press releases on the Company’s website.
Page 3
Interim report July-September 2026 CEO Comment 3 Immunovia delivered its best commercial results ever as uptake of the PancreaSure test accelerated in Q3. We added more high-risk surveillance centers than ever before, and test adoption significantly increased. We also saw very promising signs for future PancreaSure reimbursement and high interest from potential partners. Accelerating trial and growing adoption of the PancreaSure test Nine new surveillance centers began using the test this quarter. There are now 36 expert sites using PancreaSure just one year after launch. Twelve of these clinics have reached the adoption stage, meaning they have ordered 10 or more PancreaSure tests and are ordering consistently quarter after quarter. Our strategic account managers have been key in driving the rapidly growing trial and adoption of PancreaSure. After joining Immunovia three quarters ago, the sales representatives are performing at a very high level and have developed a national network of physician advocates who are fueling growth in new centers. Interest in the ASSURE registry study is also driving growth as pancreatic cancer experts are eager to utilize PancreaSure clinically while researching real-world use of the test. With strong trial among expert centers, we will now drive adoption and expand our commercial reach The third quarter marked the transition to the second phase of PancreaSure’s commercial launch. After delivering our phase one objective—initiating PancreaSure trial at expert centers—we will now drive adoption and testing volume at these expert centers by: Partnering with customers to modify their surveillance protocols to include PancreaSure, Increasing communication with existing customers to encourage weekly testing, and Expanding relationships with the nurses, genetic counselors, and support staff who drive execution at these centers. In phase two we are also expanding our focus to target large private gastroenterology group practices. This expansion follows a successful pilot in Q2 with Saratoga Schenectady Gastroenterology Associates (SSGA). Based in rural upstate New York, SSGA serves patients who live far from metro-area high-risk surveillance centers. After a successful trial with one of SSGA’s gastroenterologists, we are now expanding PancreaSure use in this group of 25 GI clinicians. Reimbursement progress on multiple fronts We made substantial progress in our efforts to secure payment for the PancreaSure test. Patient payments: Our collection rate on patient charges now greater than 80%, exceeding our expectations. Commercial insurance payments: We see promising signs of future reimbursement by private insurance companies. While we do not have coverage decisions in place, we see early indications that several private insurers will pay for the test, and they will pay more than we expected. The payment cycle is long; we need to register with each insurance company individually and frequently must appeal initial denials to secure payment. As a result, the impact of these payments is not yet fully reflected in our revenue, but we are very optimistic about future quarters. Medicare coverage: We achieved a key milestone when we submitted our application for Medicare coverage in late September. Our submission was bolstered by letters of support from four leading pancreatic cancer patient advocacy organizations: Pancreatic Cancer Action Network, Facing our Risk of Cancer Empowered, National Pancreas Foundation and the John R Lewis Legacy Institute. We will augment the submission in coming quarters as we complete additional clinical studies.
Page 4
Interim report July-September 2026 Potential partnerships in multiple areas Response to our business development outreach is very encouraging. Potential commercial partners in the U.S. are impressed by our commercial traction and our consistent of achievement of key milestones. We will share our encouraging commercial reimbursement results in coming weeks. In Asia, we are exploring a promising licensing opportunity with a Japanese life sciences company. We have entered discussions with multiple prospective partners in China who are conducting due diligence. We have also begun speaking with pharmaceutical companies with development or commercial-stage therapies for pancreatic cancer. We are exploring both research and commercial collaborations with these drug makers. Rights issue will support key milestones in 2027 Successful completion of the rights issue will provide funding critical for upcoming milestones. The issue will fund Immunovia into Q3 2027, with the potential for a longer runway with a successful exercise of the TO4 warrants. The new capital will support: ● Continued US commercialization of PancreaSure via targeted sales and marketing investments ● Ongoing clinical studies to demonstrate the clinical usefulness of PancreaSure to support reimbursement ● Working capital for general corporate purposes We continue to look for opportunities to reduce spending. In Q3, Immunovia’s burn rate of 5.0 MSEK per month was again below the company’s previously communicated guidance of 8 to 10 MSEK per month. T o maximize the impact of the new capital, we will reduce our monthly burn rate to less than 8 MSEK per month going forward, primarily through cuts in general and administrative expenses. We expect this lower burn rate to continue through at least the first half of 2027. I realize how painfully dilutive the rights issue will be for shareholders. I truly appreciate the support of our shareholders as we continue to commercialize PancreaSure and pursue our mission to improve survival rates in pancreatic cancer through early detection. 4 November 2, 2026 Jeff Borcherding President & CEO, Immunovia AB
Page 5
Interim report July-September 2026 T able of contents 5 About the report This information was submitted for publication on November 2, 2026, at 08:30 (CET). This financial statement has been produced in accordance with IFRS for the Immunovia Group which comprises Immunovia AB and the wholly-owned subsidiaries Immunovia Inc, Immunovia GmbH and Immunovia Incentive AB. Contact Immunovia AB (publ), Swedish Corporate Identity Number 556730-4299, Medicon Village, Scheelevägen 8, 223 63 Lund, Sweden helloir@immunovia.com, +46 46 2756 000 For further information please contact Jeff Borcherding, CEO and President jeff.borcherding@immunovia.com Group’s performance over the period ............................................................................6 Share information .................................................................................................................7 Incentive programs ...............................................................................................................9 Consolidated income statement, condensed.............................................................11 Consolidated comprehensive income, condensed ...................................................11 Consolidated financial position, condensed ..............................................................12 Change in consolidated equity, condensed.................................................................13 Consolidated cash flow statement, condensed.........................................................14 Consolidated key indicators ..............................................................................................15 Parent company’s income statement, condensed ...................................................16 Parent company’s comprehensive income, condensed..........................................16 Parent company’s balance sheet, condensed .............................................................17 Parent company’s cash flow statement, condensed................................................18 Notes ............................................................................................................................................19 Definitions .................................................................................................................................21 Other information………………………………………………………………………………………..22 Auditor’s Review Report .....................................................................................................24 Glossary .....................................................................................................................................25 Immunovia in brief .................................................................................................................27
Page 6
Interim report July-September 2026 6 Net sales Net sales for the third quarter amounted to 843 KSEK (101), and comprised royalties and revenues from PancreaSure tests. The quarter’s sales included contributions from both revenue streams, reflecting continued sales of PancreaSure tests alongside royalty income. T otal net sales during Q1-Q3 amounted to 1,598 KSEK (331), and comprised royalties and revenues from PancreaSure tests. Earnings Net earnings for the third quarter 2026 amounted to -17,606 KSEK (-29,744). The difference compared with the corresponding period last year mainly relates to negative financial income recognised in 2025, primarily driven by unrealized exchange rate effects on intercompany transactions used to finance operations in Immunovia Inc. In the fourth quarter of 2025, the intercompany loan between the Parent Company and Immunovia Inc. was converted into a shareholder contribution, which reduced future earnings volatility arising from exchange rate fluctuations. T otal operating expenses decreased during the quarter by 6,589 KSEK compared to the corresponding period last year and amounted to 17,675 KSEK (25,051). The decrease in operating expenses was mainly driven by lower spending on Clinical Studies and a one-time lease provision made in the corresponding period last year. Net earnings increased during Q1-Q3 by 69,718 KSEK and amounted to -58,869 KSEK (-128,587). The difference compared with the corresponding period last year mainly relates to negative financial income recognised in 2025, primarily driven by unrealized exchange rate effects on intercompany transactions used to finance operations in Immunovia Inc. T otal operating expenses decreased during the period by -3,696 KSEK compared to the corresponding period last year and amounted to -60,709 KSEK (-64,406). The decrease in operating expenses was mainly driven by lower spending on Clinical Studies and a one-time lease provision made in the corresponding period last year. Financing and cash flow Cash flow from operating activities improved compared to last year and amounted to -14,913 KSEK (-16,108), due to lower spending on clinical studies. Cash and cash equivalents as of September 30, 2026, amounted to 19,624 KSEK (26,569). Equity at the end of the period was 6,601 KSEK (-8,259) and the equity/assets ratio was 21 percent (-22). Going concern Based on the Board’s assessment, the cash balance of SEK 19.6 million at the end of the third quarter, together with expected net proceeds of approximately SEK 53 million from the Rights Issue announced on September 28 (approximately SEK 63 million before issue costs), assuming full subscription, is expected to secure the Company’s working capital needs into the second quarter of 2027. Potential additional proceeds from the exercise of warrants of series TO 4 in May 2027 could further extend this runway. In parallel, the Board is actively evaluating additional financing alternatives, including equity financing, strategic partnerships, and other sources of capital, with the objective of further strengthening the Company's liquidity position and extending its cash runway. Investments No investments have been made in intangible or tangible assets during the quarter. Nor have there been any financial investments during the quarter. Employees The average number of employees during the third quarter of 2026 was 18 (10) and at the end of the period the number of employees was 19 (12). Parent company’s performance The parent company’s earnings/loss for the third quarter amounted to -4,648 KSEK (-11,014) and Q1-Q3 amounted to -14,745 KSEK (-50,920). Equity at the end of the period was 80,379 KSEK (5,342). The Group’s performance over the period
Page 7
Interim report July-September 2026 Share information 7 The number of registered shares amounted to 672,666,892 shares at the end of the reporting period. The share’s nominal value is SEK 0.03. Share capital development Year Event T otal share capital (SEK) Change (SEK) T otal no. of shares Change in shares Nominal value (SEK) May 24, 2007 Formation 100,000.00 100,000.00 1,000,000 1,000,000 0.10 Oct 19, 2011 New share issue 105,263.00 5,263.00 1,052,630 52,630 0.10 Oct 27, 2011 Share split 5:1 105,263.00 - 5,263,150 4,210,520 0.02 July 5, 2012 New share issue 108,869.92 3,606.92 5,443,496 180,346 0.02 May 21, 2013 New share issue 122,483.76 13,613.92 6,124,188 680,692 0.02 Sep. 10, 2023 New share issue 124,899.76 2,416.00 6,244,988 120,800 0.02 Jun 5, 2014 New share issue 220,924.32 96,024.56 11,046,216 4,801,228 0.02 Aug 13, 2015 Bonus issue 552,310.80 331,386.48 11,046,216 - 0.05 Dec 17, 2015 New share issue 714,560.80 162,250.00 14,291,216 3,245,000 0.05 Sep 15, 2016 New share issue 823,728.40 109,167.60 16,474,568 2,183,352 0.05 Oct 17, 2016 New share issue 840,202.95 16,474.55 16,804,059 329,491 0.05 Oct 4, 2017 New share issue via warrants 865,902.95 25,700.00 17,318,059 514,000 0.05 June 8, 2018 New share issue 974,042.65 108,139.70 19,480,853 2,162,794 0.05 Sep 19, 2018 New share issue via warrants 976,567.65 2,525.00 19,531,353 50,500 0.05 Sep 9, 2019 New share issue via warrants 982,742.65 6,175.00 19,654,853 123,500 0.05 June 4, 2020 New share issue 1,130,154.05 147,411.40 22,603,081 2,948,228 0.05 Oct 4, 2020 New share issue via warrants 1,131,579.05 1,425.00 22,631,581 28,500 0.05 April 12, 2023 New share issue 2,264,374.90 1,132,795.85 45,287,498 22,655,917 0.05 Sept 12, 2024 Reduction of nominal value 1,358,624.94 -905,749.96 45,287,498 0 0.03 Sept 12, 2024 New share issue 5,078,645.88 3,720,020.94 169,288,196 124,000,698 0.03 Sep 13, 2024 New share issue 5,091,344.28 12,698.40 169,711,476 423,280 0.03 Jan 20, 2025 New share issue via warrants 7,857,266.28 2,765,922.00 261,908,863 92,197,387 0.03 Apr 17, 2025 New share issue via warrants 9,182,492.79 1 325 226,51 306,083,080 44,174,217 0.03 Nov 5, 2025 New share issue via shares 19,199,756.82 10,017,264.42 639,991,894 333,908,814 0.03 Nov 5, 2025 New share issue via shares 20,180,006.76 980,249.94 672,666,892 32,674,998 0.03 At the end of the period 20,180,006.76 672,666,892 0.03
Page 8
Interim report July-September 2026 8 Source: Monitor by Modular Finance AB. Compiled and processed data from Euroclear, Morningstar and the Swedish Financial Supervisory Authority, among others. Shareholders No. of shares Share (capital & votes) Avanza Pension 64 499 314 9,59% Handelsbanken Fonder 16 395 598 2,44% Søren Evald Andresen 10 780 000 1,60% Carl Borrebaeck 7 994 900 1,19% Sten Jönsson 7 800 000 1,16% Jens Henrik Jensen 7 520 328 1,12% Jeff Borcherding 7 197 536 1,07% Simon Borsos 7 021 818 1,04% Nordnet Pensionsförsäkring 5 258 562 0,78% Samatha Förvaltning AB 5 000 000 0,74% T en largest owners 139 468 056 20,73% Others 533 198 836 79,27% T otal 672 666 892 100,00% The 10 largest shareholders on 30 September, 2026
Page 9
Interim report July-September 2026 Incentive Programs 9 Immunovia has six outstanding incentive programs comprising 44,928,687 warrants. There is no dilution effect on earnings per share as long as the Group’s earnings are negative. Equity incentive program The extraordinary general meeting on November 21, 2023, resolved to adopt an equity incentive program for the Company’s management and key personnel (“ESOP 2023”), including a resolution to issue not more than 2,597,234 warrants to ensure the delivery of shares to the participants and for hedging of social security costs. 1,934,463 warrants have been allotted, and one warrant initially entitled the holder to acquire one new share in the Company at a subscription price of SEK 1.67 per share. As a result of rights issues carried out in 2024 and 2025, a recalculation of the subscription price and the number of shares that each warrant entitles to have been made. After recalculation, each option entitles the holder to subscribe for 1.18 shares at a subscription price of SEK 1.44 per share. The exercise period runs until 17 June 2034. The extraordinary general meeting on November 21, 2023, resolved to adopt an equity incentive program for the Company’s board of directors (“Board program 2023”), including a resolution to issue not more than 649,309 warrants to ensure the delivery of shares to the participants and for hedging of social security costs. 483,616 warrants have been allotted, and one warrant initially entitled the holder to acquire one new share in the Company at a subscription price of SEK 1.80 per share. As a result of rights issues carried out in 2024 and 2025, a recalculation of the subscription price and the number of shares that each warrant entitles to have been made. After recalculation, each option entitles the holder to subscribe for 1.18 shares at a subscription price of SEK 1.50 per share. The exercise period runs until 28 December 2033. As the exercise period for the incentive programs “ESOP 2023” and “Board program 2023” runs over 10 years, no full valuation in accordance with IFRS 2 was made in connection with the allocation. An IFRS 2 valuation will only be made once participants in the programs will exercise their options. The annual general meeting on May 14, 2025, resolved to adopt an equity incentive program for the Company’s management and key personnel (“ESOP 2025”), including a resolution to issue not more than 6,278,626 warrants to ensure the delivery of shares to the participants. 4,708,970 warrants have been allotted, and one warrant initially entitled the holder to acquire one new share in the Company at a subscription price of SEK 0,3485 per share. After recalculation due to rights issue of units completed in 2025, each option entitles the holder to subscribe for 1.11 shares at a subscription price of SEK 0.31 per share. The exercise period runs until May 22, 2033** . The annual general meeting on May 14, 2025, resolved to adopt an equity incentive program for the Company’s board of directors (“Board program 2025”), including a resolution to issue not more than 1,569,654 warrants to ensure the delivery of shares to the participants. 1,569,654 warrants have been allotted, and one warrant initially entitled the holder to acquire one new share in the Company at a subscription price of SEK 0,3485 per share. After recalculation due to rights issue of units completed in 2025, each option entitles the holder to subscribe for 1.11 shares at a subscription price of SEK 0.31 per share. The exercise period runs until May 22, 2033** . The annual general meeting on May 13, 2026, resolved to adopt an equity incentive program for the Company’s management and key personnel (“ESOP 2026”), including a resolution to issue not more than 28,322,818 warrants to ensure the delivery of shares to the participants. 28,322,818 warrants have been allotted, and one warrant initially entitles the holder to acquire one new share in the Company at a subscription price of SEK 0.190 per share. The exercise period runs until June 30, 2035** . The annual general meeting on May 13, 2026, resolved to adopt an equity incentive program for the Company’s board of directors (“Board program 2026”), including a resolution to issue not more than 7,080,702 warrants to ensure the delivery of shares to the participants. 7,080,702 warrants have been allotted, and one warrant initially entitled the holder to acquire one new share in the Company at a subscription price of SEK 0.190 per share. The exercise period runs until June 30, 2035. ***
Page 10
Interim report July-September 2026 10 The board of directors estimates that ”ESOP 2025” , ”Board program 2025” , “ESOP 2026” and ”Board program 2026”will incur costs for the company from an accounting perspective in accordance with IFRS 2. Personnel costs in accordance with IFRS 2 do not affect the company’s cash flow. The personnel costs in accordance with IFRS 2 are reported in the statement change in consolidated equity under the line item ‘Share-based payments’ . *Includes warrants issued for hedging of social security costs ** The holders can exercise vested options as from vesting until the date that falls eight years after the Grant Date. Exercises can however only be made during “exercise windows” that occurs 14 calendar days after each quarterly report (or if no quarterly report is published for a quarter, the last 14 calendar days in the subsequent quarter). Furthermore, for a participant that ceases to be employed or in a service relationship in the Group, vested options must be exercised within six months from the date when the participant ceased to be employed or in a service relationship in the Group. Any exercise of options always must comprise at least 25 per cent of the vested options held by the participant. *** The options shall vest on the date of the company’s annual general meeting 2027, provided that the participant is still a board member in the company on said date. In the event of an exit event (as defined in the program) occurring prior to the annual general meeting 2027, the options will vest immediately and in their entirety on the date such exit event is completed. The options shall expire on the date that falls eight years after the grant date. If an exit event has not occurred on or prior to such date, all options shall hence automatically lapse upon the expiration of such eight-year period. Breakdown of outstanding incentive programs Incentive program Decision date Subscription period Number of outstanding warrants Maximum number of shares to be issued Subscription price/ share Change in share capital at full utilization Board program 2023 Nov 21, 2023 Until December 28, 2033 649,309 766,185 1.50 22,985.54 ESOP 2023* Nov 21, 2023 Until June 17, 2034 2,597,234 3,064,736 1.44 91,942.08 Board program 2025** May 14, 2025 Until May 22, 2033 1,569,654 1,742,316 0.31 52,269.48 ESOP 2025** May 14, 2025 Until May 22, 2033 4,708,970 5,226,957 0.31 156,808.70 Board program 2026*** May 13, 2026 Until May 22, 2035 7,080,702 7,080,702 0.19 212,421.06 ESOP 2026 May 13, 2026 Until May 22, 2035 28,322,818 28,322,818 0.19 849,684.54 T otal 44,928,687 46,203,714 1,386,111.40
Page 11
Interim report July-September 2026 11 Consolidated income statement, condensed SEK thousands 2026 Jul-Sep 2025 Jul-Sep 2026 Jan-Sep 2025 Jan-Sep 2025 Full year Operating income Net sales 843 101 1,598 330 685 Other operating income 45 0 118 68 67 T otal operating income 888 101 1,716 398 752 Operating expenses Costs of goods sold -307 -36 -693 -36 -136 Other external expenses -9,065 -14,714 -29,937 -35,942 -43,527 Personnel costs -8,540 -9,952 -27,838 -25,922 -34,201 Amortization of tangible and intangible assets -637 -450 -2,194 -1,651 -2,325 Other operating expenses -18 0 -46 -856 -948 T otal operating expenses -18,568 -25,152 -60,709 -64,406 -81,137 Operating earnings/loss -17,680 -25,051 -58,993 -64,009 -80,385 Profit/loss from financial items Financial income 74 11 123 48 540 Financial expenses* 0 -4,705 0 -64,628 -66,072 T otal financial items 74 -4,694 0 -64,580 -65,530 Earnings/loss after financial items -17,606 -29,744 -58,870 -128,587 -145,915 Income tax 0 0 0 0 0 Earnings/loss for the period -17,606 -29,744 -58,870 -128,587 -145,915 Earnings per share before dilution (SEK) -0.03 -0.10 -0.09 -0.48 -0.42 Earnings per share after dilution (SEK) -0.03 -0.10 -0.09 -0.48 -0.41 Average number of shares 672,666,892 297,830,754 672,666,892 269,781,484 344,324,462 Number of shares at year’s end 672,666,892 306,083,080 672,666,892 306,083,080 672,666,892 Consolidated comprehensive income, condensed SEK thousands 2026 Jul-Sep 2025 Jul-Sep 2026 Jan-Sep 2025 Jan-Sep 2025 Full year Earnings/loss for the period -17,606 -29,744 -58,870 -128,587 -145,915 Exchange rate differences for foreign net investment 0 4,157 0 60,779 60,799 Other comprehensive income 0 4,157 0 60,779 60,799 Comprehensive income for the period -17,606 -25,587 -58,870 -67,806 -85,136 *The difference in Earnings/loss for the period mainly reflects unrealized exchange rate losses on intercompany financing in 2025. The loan was converted into a shareholder contribution in Q4 2025.
Page 12
Interim report July-September 2026 12 Consolidated financial position, condensed SEK thousands 2026 Sep 30 2025 Sep 30 2025 Dec 31 ASSETS Non-current assets Intangible non-current assets 6,066 7,012 6,715 T angible non-current assets 3,059 1,493 965 Financial non-current assets 138 130 127 T otal non-current assets 9,263 8,635 7,807 Current assets Inventory 439 179 119 Account receivables 401 0 39 Other short term receivables 2,368 2,272 2,788 Cash and cash equivalents 19,624 26,569 77,459 T otal current assets 22,832 29,020 80,405 TOTAL ASSETS 32,095 37,655 88,212 EQUITY AND LIABILITIES Equity Share capital 20,180 9,182 20,180 Other contributed capital 1,308,996 1,229,694 1,308,996 Translation reserve 16,675 16,646 16,592 Retained earnings incl. total comprehensive income -1,339,250 -1,263,781 -1,281,003 T otal equity 6,601 -8,259 64,735 Provisions Other provisions 7,784 7,784 7,784 T otal provisions 7,784 7,784 7,784 Current liabilities Interest-bearing liabilities 2,932 20,366 857 Other liabilities 14,778 25,548 14,836 T otal current liabilities 17,710 45,914 15,693 TOTAL EQUITY AND LIABILITIES 32,095 37,655 88,212
Page 13
Interim report July-September 2026 13 Change in consolidated equity, condensed SEK thousands Share capital Other contributed equity Translation reserve Retained earnings T otal equity Opening balance January 1, 2025 5,091 1,186,063 -44,134 -1,135,371 11,649 Comprehensive income for the period 60,780 -128,586 -67,806 Transactions with owners in their capacity as owners 0 New share issue 4,091 48,568 52,659 Issue costs -4,937 -4,937 Share-based payments 176 176 Closing balance September 30, 2025 9,182 1,229,694 16,646 -1,263,781 -8,259 Comprehensive income for the period -54 -17,329 -17,383 Transactions with owners in their capacity as owners 0 New share issue 10,998 99,331 110,329 Issue costs -20,029 -20,029 Share-based payments 77 77 Closing balance December 31, 2025 20,180 1,308,996 16,592 -1,281,033 64,735 Comprehensive income for the period -58,865 -58,865 Transactions with owners in their capacity as owners 0 Translation differences 88 -148 -60 New share issue 0 Issue costs 0 Share-based payments 791 791 Closing balance September 30, 2026 20,180 1,308,996 16,680 -1,339,255 6,601
Page 14
Interim report July-September 2026 14 Consolidated cash flow statement, condensed SEK thousands 2026 Jul-Sep 2025 Jul-Sep 2026 Jan-Sep 2025 Jan-Sep 2025 Full year Operating activities Operating earnings/loss -17,680 -25,050 -58,992 -64,008 -80,384 Adjustment for items not included in cash flow 1,101 -415 2,982 6 907 Interest received 78 11 127 48 540 Interest paid 0 -500 0 -500 -2,042 T ax paid 0 0 0 0 0 Cash flow from operating activities before changes in working capital -16,501 -25,965 -55,883 -64,454 -80,979 Cash flow from changes in working capital Change in inventory 122 -181 -293 -181 -123 Change in operating receivables 153 1,052 161 899 310 Change in operating liabilities 1,316 8,986 -354 5,120 2,392 Cash flow from operating activities -14,910 -16,108 -56,369 -58,616 -78,400 Investment activities Investment in intangible assets 0 -5,559 0 -5,559 -5,559 Investment in tangible assets 0 0 0 0 0 Investment in financial assets 0 0 0 0 0 Sale of non-current assets 0 0 0 0 0 Other long term receivables 0 -134 0 -134 -134 Cash flow from investment activities 0 -5,693 0 -5,693 -5,693 Financing activities Amortization of leasing liability -391 113 -1,144 -693 -1,202 New share issue 0 0 0 47,722 138,022 New loans raised 0 19,000 0 19,000 19,000 Amortization loans 0 0 0 0 -19,000 Cash flow from financing activities -391 19,113 -1,144 66,029 136,820 Cash flow for the period -15,301 -2,688 -57,513 1,720 52,727 Cash and cash equivalents at start of period 34,900 29,269 77,459 25,318 25,318 Exchange rate difference in cash and cash equivalents 26 -12 -321 -469 -586 Cash and cash equivalents at end of period 19,624 26,569 19,624 26,569 77,459
Page 15
Interim report July-September 2026 15 Consolidated key indicators 2026 Jul-Sep 2025 Jul-Sep 2026 Jan-Sep 2025 Jan-Sep 2025 Full year Operating earnings/loss (SEK 000) -17,680 -25,051 -58,993 -64,009 -80,385 Earnings/loss for the year (SEK 000) -17,606 -29,744 -58,870 -128,587 -145,914 Earnings per share before dilution (SEK) -0.03 -0.10 -0.09 -0.48 -0.42 Earnings per share after dilution (SEK) -0.03 -0.10 -0.09 -0.48 -0.41 Cash and cash equivalents at the period’s end (SEK 000) 19,624 26,569 19,624 26,569 77,459 Cash flow from operating activities (SEK 000) -14,910 -16,108 -56,369 -58,616 -78,400 Cash flow for the period (SEK 000) -15,301 -2,688 -57,513 1,720 52,727 Equity (SEK 000) 6,601 -8,259 6,601 -8,259 64,735 Equity per share (SEK) 0.01 -0.03 0.01 -0.03 0.10 Equity / assets ratio (%) 21% -22% 21% -22% 72% Average number of employees 18 10 18 9 10
Page 16
Interim report July-September 2026 16 Parent company’s income statement, condensed SEK thousands 2026 Jul-Sep 2025 Jul-Sep 2026 Jan-Sep 2025 Jan-Sep 2025 Full year Operating income etc. Net sales 502 90 804 319 567 Other operating income 43 0 116 68 67 T otal operating income 545 90 921 387 634 Operating expenses Other external expenses -4,174 -8,714 -13,277 -18,672 -18,731 Personnel costs -907 -603 -2,057 -5,439 -5,924 Amortization of intangible and tangible non-current assets -97 -97 -291 -291 -387 Other operating expenses -18 -6 -46 -42 -53 T otal operating expenses -5,196 -9,419 -15,671 -24,442 -25,095 Operating earnings/loss -4,651 -9,329 -14,750 -24,055 -24,461 Profit/loss from financial items Result from shares in group companies 0 0 0 28,875 28,875 Financial incomes 3 2,973 5 8,895 9,394 Financial expenses 0 -4,658 0 -64,635 -66,153 T otal financial items 3 -1,685 5 -26,865 -27,884 Earnings/loss after financial items -4,648 -11,014 -14,745 -50,920 -52,345 Allocations Group contributions received 0 0 0 0 0 T otal allocations 0 0 0 0 0 Earnings/loss before tax -4,648 -11,014 -14,745 -50,920 -52,345 Income tax 0 0 Earnings/loss for the period -4,648 -11,014 -14,745 -50,920 -52,345 Parent company’s comprehensive income, condensed SEK thousands 2026 Jul-Sep 2025 Jul-Sep 2026 Jan-Sep 2025 Jan-Sep 2025 Full year Earnings/loss for the period -4,648 -11,014 -14,745 -50,920 -52,345 Other comprehensive income 0 0 0 0 0 Comprehensive income for the period -4,648 -11,014 -14,745 -50,920 -52,345
Page 17
Interim report July-September 2026 17 Parent company’s balance sheet, condensed SEK,thousands 2026 Sep 30 2025 Sep 30 2025 Dec 31 ASSETS Non-current assets Intangible non-current assets 653 1,012 922 T angible non-current assets 3 31 24 Financial non-current assets 85,042 303 29,692 T otal non-current assets 85,698 1,346 29,692 Current assets Receivables from Group companies 2,059 14,439 2,191 Current receivables 673 857 1,053 Prepaid expenses and accrued income 200 565 514 Cash and cash equivalents 7,811 23,517 73,018 T otal current assets 10,743 39,378 76,775 TOTAL ASSETS 96,441 40,724 107,413 EQUITY AND LIABILITIES Restricted equity Share capital 20,180 9,182 20,180 T otal restricted equity 20,180 9,182 20,180 Non-restricted equity Premium fund 0 43,631 123,225 Retained earnings including comprehensive income 60,199 -47,471 -49,072 T otal non-restricted equity 60,199 -3,840 74,153 T otal equity 80,379 5,342 94,333 Provisions Other provisions 7,784 7,784 7,784 T otal provisions 7,784 7,784 7,784 Current liabilities Interest-bearing liabilities 0 19,000 0 Other liabilities 8,278 8,597 5,295 T otal current liabilities 8,278 22,597 5,295 TOTAL EQUITY AND LIABILITIES 96,441 40,724 107,413
Page 18
Interim report July-September 2026 18 Parent company’s cash flow statement, condensed SEK thousands 2026 Jul-Sep 2025 Jul-Sep 2026 Jan-Sep 2025 Jan-Sep 2025 Full year Operating activities Operating earnings/loss -4,651 -9,328 -14,750 -24,055 -24,462 Adjustment for items not included in cash flow 561 96 1,082 290 679 Interest received 3 0 5 44 533 Interest paid 0 -500 0 -500 -2,010 T ax paid 0 0 0 0 0 Cash flow from operating activities before changes in working capital -4,087 -9,732 -13,664 -24,221 -25,260 Cash flow from changes in working capital Change in inventory 0 0 0 0 0 Change in operating receivables 134 47 932 -24,932 -27,383 Change in operating liabilities 2,416 3,456 2,875 -1,684 -4,984 Cash flow from operating activities -1,537 -6,229 -9,856 -50,837 -57,627 Investment activities Investment in intangible non-current assets 0 0 0 0 0 Investment in tangible non-current assets 0 0 0 0 0 Investment in financial non-current assets -19,618 0 -55,351 0 -29,388 Sale of non-current assets 0 -14,439 0 -14,439 0 Cash flow from investment activities -19,618 -14,439 -55,351 -14,439 -29,388 Financing activities New share issue 0 0 0 47,781 138,022 New loans raised 0 19,000 0 19,000 19,000 Amortization loans 0 0 0 0 -19,000 Cash flow from financing activities 0 19,000 0 66,781 138,080 Cash flow for the period -21,155 -1,668 -65,207 1,505 51,007 Cash and cash equivalents at start of period 28,966 25,185 73,018 22,011 22,011 Cash and cash equivalents at period’s end 7,811 23,517 7,811 23,517 73,018
Page 19
Interim report July-September 2026 Notes 19 NOTE 1 ACCOUNTING PRINCIPLES The Group applies the Swedish Annual Accounts Act and International Financial Reporting Standards (IFRS(R) Accounting Standards) as adopted by the EU, and RFR 1 complementary accounting rules for Groups when preparing financial reports. The parent company applies the Swedish Annual Accounts Act, ÅRL kap 9 and RFR 2 Accounting for legal entities when preparing financial reports. The applied accounting principles are consistent with those applied in the 2025 annual report. This interim report has been prepared in accordance with IAS 34 interim financial reporting, and applicable sections of the Swedish Annual Accounts Act (ÅRL kap 9 and RFR 2). New and amended standards adopted with effect from 2026 are not expected to have any significant impact on the Group’s financial position. IFRS 18 Presentation and Disclosure in Financial Statements, which will be effective for annual reporting periods beginning on or after 1 January 2027, is expected to affect the presentation and disclosure of the Group’s financial performance in the financial statements. The Group is currently assessing the impact of adopting this standard. NOTE 2 OTHER INFORMATION Financial instruments The Group currently has no financial instruments valued at fair value. Instead, all financial assets and liabilities are measured at amortized cost. It is estimated that there are no significant differences between fair value and book value relating to financial assets and liabilities. Revenue recognition Net sales for the period comprised royalty income and sales of PancreaSure tests. Revenue from PancreaSure tests is recognized upon delivery of the test results, while royalty income is recognized as the royalties accrue. In the corresponding period last year, net sales consisted of both PancreaSure tests and royalty income. Transactions with related parties From time to time, board members may undertake specific assignments that do not belong to the board’s normal duties, which are either decided at the annual general meeting or by the board jointly. During January-September 2026, no such assignments or other material related party transactions took place, other than Board fees to the Board of Directors and ordinary remuneration to key management personnel. Leases and provisions The group has leasing agreements, mainly in the form of agreements for the use of office premises, where one of the agreements extends to 31 October 2028 with a quarterly fee of SEK 1,557,000. With the decision to cease the commercialization of the IMMray™ PanCan-d test and to wind down the business, there has been a need to renegotiate the said lease agreement. As per December 31, 2023, with a revaluation effect resulting in that the right-of-use asset as well as the lease liability was reduced by approximately 20 MSEK. The remaining right-of-use asset as well as the leasing liability as of December 31, 2023 was reported based on a calculated and assessed probable leasing obligation for 2024 totaling approximately 8 MSEK. From the end of September 2024, these premises are no longer in use. The letter of intent with the landlord remains. Due to the fact that the Group no longer has control of the premises, the remaining lease liability of approximately SEK 5 million has been reclassified to Other provisions by the end of the third quarter 2024. After a reassessment of the probable outcome of the contract, the total Other provisions reported as of 30 September 2026 amount to 7.8 MSEK and correspond to an assessment of the probable outcome based on agreements with the landlord. The remaining unreserved, undiscounted, value of the contract amounts to approximately 5.1 MSEK. The parent company reports the corresponding provision.
Page 20
Interim report July-September 2026 Notes 20 Remaining leasing debt for other leasing agreements, is included in other interest-bearing liabilities and amounts to approximately 3.1 MSEK and refers to leasing contracts in the USA. New/ existing contracts in Sweden fall under short-term contracts and contracts of reduced value. Risks Through its operations, Immunovia is exposed to both operational and financial risks. The following risks and uncertainty factors may have a negative impact on the Company’s operations, financial position and/or results. The company’s risks are also described in the Annual Report 2025, page 29. Operational risks Immunovia’s operations and market are subject to several risks that could negatively impact the company. The risks are related to Immunovia’s operations, industry and market, legal and regulatory risks, and financial risks. After launching the PancreaSure test in 2025, Immunovia faces several risks as it seeks to drive adoption of the test and secure reimbursement. The risk factors below are described without ranking and without claiming to be comprehensive. Market adoption: T o drive PancreaSure test adoption, Immunovia must convince physicians to change their approach to high-risk surveillance to incorporate a blood test along with, or in place of, imaging. This process of changing of protocols and behavior can be difficult. PancreaSure’s commercial success in 2026 will depend on the performance of its small, targeted sales team, which was hired in Q1 2026. T o fully capitalize on the volume potential of the PancreaSure test, Immunovia must secure a commercial partnership with a large diagnostics company. Clinical: Immunovia has successfully completed three clinical validation studies of the PancreaSure test. The next challenge is to demonstrate the clinical utility of the test in prospective studies, showing that the test impacts physician decisions and leads to better clinical outcomes for patients. Reimbursement: Generating meaningful PancreaSure revenue will require securing positive coverage decisions from Medicare and private commercial payers. Failure to secure coverage would substantially limit average sales price per test and total revenue. Competition: Immunovia’s early detection test competes directly with pancreatic cancer detection tests and several multi-cancer early detection tests. Most of these competitors are better funded than Immunovia, enabling these competitors to deploy larger sales teams and to conduct larger and more costly clinical studies. Currency risks The Company operates both nationally and internationally, which results in exposure to currency exchange rate fluctuations mainly related to USD, CHF and EUR. Currency risk relates to future business transactions and assets and liabilities on the balance sheet. Interest risk in cash flow Interest rate risk is the risk that the value of financial instruments varies due to changes in market interest rates. The group currently only has interest-bearing financial assets in the form of bank balances and interest-bearing liabilities in the form of leasing debt for premises. Liquidity risk and going concern Based on the Board’s assessment, the cash balance of SEK 19.6 million at the end of the third quarter, together with expected net proceeds of approximately SEK 53 million from the Rights Issue announced on September 28 (approximately SEK 63 million before issue costs), assuming full subscription, is expected to secure the Company’s working capital needs into the second quarter of 2027. Potential additional proceeds from the exercise of warrants of series TO 4 in May 2027 could further extend this runway. In parallel, the Board is actively evaluating additional financing alternatives, including equity financing, strategic partnerships, and other sources of capital, with the objective of further strengthening the Company's liquidity position and extending its cash runway.
Page 21
Interim report July-September 2026 Definitions 21 Key indicator Definition Motivation for using financial key indicator not defined pursuant to IFRS Net sales Revenues from goods and services sold, and royalties received relating to the main activity during the relevant period. Operating earnings/loss Earnings/loss before financial items and tax. Operating earnings/loss provides a view of the earnings that the company’s ordinary activities have generated. Basic and diluted earnings per share Earnings/loss divided by the weighted number of shares in the period before and after dilution respectively. Average number of shares before and after dilution The average number of outstanding shares in the period before and after dilution respectively. Because the group is generating a loss, there is no dilution, despite the subscription price being lower than the share price. Cash and cash equivalents Cash and bank balances. Cash flow from operating activities Cash flow before cash flow from investing activities and financing activities. Cash flow for the period The change in cash and cash equivalents for the period excluding effective unrealized exchange rate gains and exchange rate losses. Equity per share (SEK) Equity divided by the number of shares at the end of the period. Management follows this indicator to monitor the value of equity per share. Equity/assets ratio Equity as a percentage of total assets. Management follows this indicator of the company’s financial stability. Average number of employees The average of the number of employees in the of working-hours in the period divided by scheduled working hours for the period.
Page 22
Interim report July-September 2026 22 Review This interim report has been reviewed by the company’s auditors. Financial calendar ● Year-end Report Q4 2026, Thursday February 11, 2027 ● Annual report 2026, Wednesday March 24, 2027 ● Annual general meeting, Wednesday April 28, 2027 ● Q1 interim report 2027, Wednesday May 5, 2027 ● Q2 interim report 2027, Thursday August 5, 2027 ● Q3 interim report 2027, Thursday November 4, 2027 ● Financial statement 2027, Thursday February 10, 2028 Contact information: Immunovia AB (publ), Medicon Village, Scheelevägen 8, 223 63 Lund, Sweden T el: +46 46 275 60 00 Email: helloir@immunovia.com Web: www.immunovia.com For further information please contact Jeff Borcherding, CEO and President jeff.borcherding@immunovia.com The company’s Annual Report is available for download on the company’s website: www.immunovia.com This information is information that Immunovia is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-11-02 08:30 CET. Other information Conference call Immunovia will hold a webcast teleconference at 15:00 CET on November 2 with Jeff Borcherding, CEO and President. T o join the call, use the webcast link below: https://events.teams.microsoft.com/event/1274ea2b-3f72-42e8-b9bb-128cd05bf932@4108bd4b-5f9f-40d 6-bfff-a07cc8682f85?source=copyLinkOneEventsShareDialog
Page 23
Interim report July-September 2026 23 The Board and the CEO certify that the interim report gives a true and fair view of the company’s and the Group’s operations, position and results, and describes significant risks and uncertainties that the company and the companies making up the Group face. Lund November 2, 2026 Peter Høngaard Andersen Chairman of the board Bryan Riggsbee Board member Melissa Farina Board member Jeff Borcherding CEO & President Hans Johansson Board member Martin Møller Board member Valerie Bogdan-Powers Board member
Page 24
Interim report July-September 2026 24 Introduction We have reviewed the accompanying balance sheet of Immunovia AB (publ) as of September 30, 2026 and the related statements of income, changes in equity and cash flows for the nine-month period then ended, and a summary of significant accounting policies and other explanatory notes. Management is responsible for the preparation and fair presentation of this interim financial information in accordance with IAS 34 and the Annual Accounts Act. Our responsibility is to express a conclusion on this interim financial information based on our review. Scope of Review We conducted our review in accordance with International Standard on Review Engagements 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity. ” A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. Conclusion Based on our review, nothing has come to our attention that causes us to believe that the accompanying interim financial information does not present fairly, in all material respects, the financial position of the entity as at September 30, 2026, and of its financial performance and its cash flows for the nine-month period then ended in accordance with IAS 34 and the Annual Accounts Act. Material Uncertainty Related to Going Concern Without affecting our conclusions above, we draw attention to the disclosures in the interim report under the headings “Going concern” and “Liquidity risk and Going concern” , where the company explains that its future financing depends on the outcome of the forthcoming share issue to secure its funding. However, if the outcome is not as expected, this indicates that a material uncertainty exists regarding the company’s ability to continue as a going concern. Our conclusion is not modified in respect of this matter. Stockholm, according to date in electronical signature Grant Thornton Sweden AB Therese Utengen Authorized Public Accountant Auditor’s Review Report
Page 25
Interim report July-September 2026 Glossary 25 Antigen - A foreign body substance that elicits a reaction of the immune system in contact with the organism. The substance may be a chemical substance, a protein or a carbohydrate. Antibodies – Antibodies, or immunoglobulins, are a type of protein used by the body´s immune system to detect and identify foreign substances such as viruses, bacteria or parasites. Benign – If a tumor is benign it means that the tumor is not dangerous and will not spread. Bioinformatics – Bioinformatics is an interdisciplinary field in which algorithms are developed for the analysis of biological (especially molecular biology) data. Biomarker – A biomarker can be defined as a biological response to a change caused by disease or foreign substance. Biomarkers can be used as early warning signs of biological changes in an organism. CAP - College of American Pathologists. The CAP has deemed status under CLIA to accredit laboratories performing testing on specimens from human beings or animals, using methodologies and clinical application within the expertise of the program. Laboratories must be appropriately licensed to perform testing when required by law. CLIA - Clinical Laboratory Improvement Amendments. The Centers for Medicare & Medicaid Services (CMS) regulates all laboratory testing performed on humans in the U.S. through the Clinical Laboratory Improvement Amendments (CLIA). The objective of the CLIA program is to ensure quality laboratory testing. All clinical laboratories must be properly certified to receive Medicare or Medicaid payments. Discovery Trial – Research carried out in order to verify a special hypothesis. Histology – Histology is the study of biological tissue. Invasive – Invasive means to penetrate or attack. Invasive medical examinations refer to examinations that include any form of penetration through a hole in the body or surgical operation. Malignant – Malignant tumors tend to worsen and become mortal. They are termed cancer, and thus differ from benign tumors. Metastasis – A metastasis is a tumor that has spread to other organs. Microarray – A microarray is a molecular biology test format for simultaneously measuring the relative concentrations of proteins. Molecular Diagnosis – A collection of technologies used to analyze biological markers at the genomic and protein levels (i.e., the genetic code of individuals and how their cells express their genes as proteins in the body), using molecular biology for medical testing. These technologies are used to diagnose and monitor disease, detect the risk of disease and to determine which treatment is likely to work best for the individual. NOD type 2 – New Onset Diabetes type 2. NPV– Negative Predictive Value. NSCLC – Non-Small Cell Lung Cancer, the most common type of lung cancer, 80-85% of all lung cancer cases.
Page 26
Interim report July-September 2026 26 Palliative care – Palliative care is administered when the patient’s disease is beyond the ability to cure. The purpose of palliative care is to provide support to patients and families using both psychological and medical practices. Pancreatologist – Doctor specializing in diseases relating to the pancreas. PDAC– Pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer. Prospective trial – A trial in which a group of individuals is studied and followed often for a long time to see how a particular disease develops. A prospective trial is used to study the relationship between different risk factors and a certain disease. You follow individuals with and without risk factors going forwards over time. At the end of the trial, the proportion of individuals in the two groups who developed disease is compared. Proteomics – Proteomics is a branch of biology and includes surveys of large amounts of data about proteins. Reproducibility – Within the field of statistics, reproducibility is described as the correlation between results from repeated measurements performed by different observers with different instruments of the same type, which measurements are performed in order to reject any measurement error due to materials and personnel. Resectable – Able to be removed by surgery. Retrospective study – A study in which the focus is on something that has happened in the past, i.e. using historic data. This form of study starts with the answer, i.e. it is known which individuals became ill and which did not. Screening – Screening refers to medical examinations to identify a disease. It is normally carried out before the patient has exhibited obvious symptoms. Self-pay customers – Patients or organizations that pay without reimbursement from insurance companies or authorities. Sensitivity – Sensitivity is a statistical measure of the reliability of a binary diagnostic test and the probability that a generated positive result is correct. Serum – A serum is a transparent yellowish liquid obtained by allowing the blood to clot, and then removing the blood cells and the coagulation proteins. Serum contains proteins, including antibodies. Specificity – Specificity is a statistical measure of the reliability of a binary diagnostic test and the probability that the generated negative result is de facto negative.
Page 27
Interim report July-September 2026 Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer. USA is the world’s largest market for detection of pancreatic cancer. The company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing. Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.